Market Cap (In USD)
457.14 Million
Revenue (In USD)
-
Net Income (In USD)
-36.31 Million
Avg. Volume
131.95 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 14.01-74.49
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US64135M1053
- CUSIP
- 64135M105
- CIK
- 1404644
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Rachel L. McMinn Ph.D.
- Employee Count
- -
- Website
- https://www.neurogene.com
- Ipo Date
- 2014-03-07
- Details
- Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
More Stocks
-
PCLOFPharmaCielo Ltd.
PCLOF
-
8620
-
CBSTF
-
BJCHF
-
BIBLFWaterloo Brewing Ltd.
BIBLF
-
BTURF
-
SBOK
-
GLOBALVECTGlobal Vectra Helicorp Limited
GLOBALVECT